Track topics on Twitter Track topics that are important to you
Cullgen, a US-Japan-China small-molecule drug startup, announced a Seed Financing of up to $15 million from GNI Group. Cullgen plans to develop drugs based on its ubiquitin-mediated protein degradatio...
Cullgen Inc. has been formed by GNI Group Ltd., which will seed the drug discovery firm with up to $15mm.
Cullgen Inc., a biopharmaceutical company focusing on developing new drugs using protein degradation technology today announced that the laboratories of its co-founders, Dr. Jian ...
Cullgen Inc. announced a Series Seed Financing of up to $15M by GNI Group Ltd. (GNIG) (TOKYO: 2160) to build a new drug discovery platform based on advanced ubiquitin-mediated pro...
Deals and Financings Grail, an Illumina diagnostic spinout that raised $1 billion in venture capital and merged with Cirina of Hong Kong, is in discussions for a $500 million Hong Kong IPO; Viela Bi...
Cullgen is a drug discovery company leveraging ubiquitin-mediated, small molecule-induced protein degradation technology. The company's research programs focus on novel treatment ...
We have published hundreds of Cullgen Inc. news stories on BioPortfolio along with dozens of Cullgen Inc. Clinical Trials and PubMed Articles about Cullgen Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cullgen Inc. Companies in our database. You can also find out about relevant Cullgen Inc. Drugs and Medications on this site too.
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...